Articles tagged with Lung Cancer
Patients with high EGFR expression have a survival advantage when treated with cetuximab plus chemotherapy, living up to 12 months on average. In contrast, those with low EGFR expression show no difference in overall survival.
A study found that organ transplant recipients have a doubled cancer risk compared to the general population, with increased risks for various types of malignancies, including non-Hodgkin lymphoma and lung cancer. The increased risk is attributed to immunosuppression and oncogenic viral infections.
The algorithm identifies high-risk patients for gastro-oesophageal and lung cancers at an earlier stage by analyzing symptoms and risk factors. It shows that the top 10% of predicted patients accounted for 77% of all diagnosed cases over two years.
A study published in JAMA suggests that CT scans used for lung cancer screening can help identify chronic obstructive pulmonary disease (COPD) in heavy smokers. The research found that adding an expiratory CT scan to the baseline inspiratory scan improved diagnostic accuracy, particularly for individuals with severe obstruction.
Researchers found that UK doctors are reluctant to cite smoking as a cause of death on death certificates due to concerns about stigmatizing the deceased. In contrast, alcohol was cited as a cause in over half of cases linked to excessive drinking.
A phase 2 trial shows that combining standard chemotherapy with a new cancer vaccine enhances treatment effect and slows disease progression in NSCLC patients. The vaccine stimulates an immune response against the MUC1 protein, which is overexpressed in 60% of NSCLCs.
The Boston University School of Medicine is developing novel technologies to detect lung cancer early, using advanced imaging techniques and molecular biomarkers. The goal is to reduce mortality among high-risk individuals by identifying those at risk for future development of the disease.
Researchers found that lung cancer patients with diabetes had higher survival rates, including 43% at 1-year and 28% without diabetes. The benefits were seen across different stages of disease, suggesting that diabetes may not be a reason to withhold standard treatment.
A new system being developed by researchers at the University of Strathclyde could administer drugs to lung cancer patients more efficiently without harmful side effects. The approach involves delivering treatment via nebulisation, potentially leading to improved patient outcomes and reduced mortality rates.
Advanced PET scans can identify aggressive tumors and predict patient prognosis, potentially intensifying treatment for patients with locally advanced lung cancer. The study found a strong correlation between radiation dose intensity and local control of the cancer.
Researchers have developed a virtual fly-through 3D imaging technique that accurately detects regional lymph node metastases in non-small cell lung cancer patients. The method achieved an 81% diagnostic accuracy rate, making it a promising tool for non-invasive diagnosis.
A randomized phase III trial found that higher doses of radiation therapy do not improve overall survival for stage III non-small cell lung cancer patients. The standard dose of radiation therapy (60 Gy) was shown to be sufficient and effective in treating the disease.
A new type of MRI scan, diffusion-weighted MRI, has been shown to be more accurate in detecting lung cancer than current PET-CT scans. This non-invasive technique measures water movement in lung tissue and can detect structural changes caused by cancer even in early stages.
A French study found professional goat exposure increases risk of pneumonic-type lung adenocarcinoma (P-ADC) fivefold compared to other lung cancers. P-ADC is more common in females and those with no smoking history.
A University of Kentucky research team, led by Dr. Susanne Arnold, has been awarded a $1.43 million grant to investigate potential environmental factors contributing to the high lung cancer rates in Eastern Kentucky. The study will examine exposure to trace elements and their role in promoting carcinogenesis.
Researchers at the University of Missouri have developed a nanotechnology sensor that can detect lung cancer in blood plasma with high sensitivity and selectivity. This technology could provide an earlier warning signal, potentially saving lives. The sensor detects changes in a specific microRNA molecule associated with lung cancer.
Researchers have identified protein signatures in mouse blood samples that reflect lung cancer biology in humans, paving the way for better monitoring of tumor progression and potential early detection strategies. The study's findings also suggest that these signatures may be useful in detecting lung cancer at an earlier stage.
Researchers at Brigham and Women's Hospital have identified a new combination of targeted therapies that successfully treat two aggressive tumor types: neurofibromatosis type 1 and KRAS-mutant lung cancer. The treatment promotes dramatic tumor regression by targeting cancer cells from two different angles.
A new study found that lung cancer patients treated in hospitals with high safety-net burden faced significantly lower rates of curative-intent surgery compared to those at low-safety-net burden facilities. The disparity persisted even after controlling for other factors.
A study published in The Lancet found that World Trade Center-exposed New York City male firefighters are 19% more likely to have cancer compared to their non-exposed colleagues, as well as a comparable sample of the general population. The study analyzed data from 9853 male firefighters and found increased cancer incidence rates in WT...
A study found that ALK-rearranged non-small cell lung cancer patients responded significantly better to pemetrexed than those without the genetic mutation. Researchers discovered that ALK positivity was an independent predictor for pemetrexed efficacy, with improved tumor response rates and longer time to progression.
A study of nearly 100 studies supports thermal ablation as a successful alternative to surgery and radiation therapy for patients with advanced lung cancer. The procedure has achieved an overall survival rate of 48-80 percent at two years, offering a safe and effective treatment option.
Researchers found that smokers who light up within 30 minutes of waking have a higher risk of developing lung and head and neck cancers. This increased risk is independent of smoking frequency and duration, suggesting that nicotine dependence may play a role in cancer development.
Researchers have found that sniffer dogs can reliably detect lung cancer by identifying volatile organic compounds in patients' breath. The study, published in the European Respiratory Journal, used trained dogs to detect lung cancer with an accuracy rate of 71%, surpassing current detection methods.
A CAMH study found that a specific gene combination significantly increases lung cancer risk, particularly among light smokers with two high-risk variants of the nicotine metabolic and nicotinic genes. The genetic risk was higher in lighter smokers, suggesting a need for targeted interventions to reduce lung cancer risk.
Smokers who light up within 30 minutes of waking are 1.79 times more likely to develop lung cancer and 1.59 times more likely to develop head and neck cancer compared to those who delay smoking for over an hour. Targeted smoking cessation programs may help reduce tobacco's negative health effects.
A new study published in The Lancet found that platinum-based doublet chemotherapy is associated with improved survival rates for elderly patients with non-small-cell lung cancer. The treatment showed better results compared to monotherapy in patients over 70 years old, suggesting a potential shift in the current treatment strategy for...
A new, cost-effective method for detecting ALK rearrangement in non-small cell lung cancer patients has been developed. This approach is comparable to the established gold standard, fluorescence in situ hybridization (FISH), and could enable more patients to access potentially life-saving crizotinib therapy.
The OPTIMAL trial found erlotinib significantly prolonged median progression-free survival compared to chemotherapy (13.1 months vs 4.6 months). Serious treatment-related side effects were also more common in patients receiving chemotherapy.
Researchers have identified a way to exploit brain's self-repair mechanism to protect nerve cells and enhance brain repair after stroke. Estradiol has been shown to protect male rats against beta-cell failure in rodent models of type 2 diabetes, suggesting estrogen receptors as a viable therapeutic target.
A new study published in the Journal of Thoracic Oncology found that endosonography followed by surgical staging significantly improved the quality of life for lung cancer patients. The study, which compared two strategies for mediastinal staging, showed no significant difference in costs between the two approaches.
The TEMLA procedure demonstrated a higher diagnostic yield than EBUS and EUS in detecting cancer in primary staging, with a sensitivity of 98.6% compared to 88.9% for EBUS/EUS. Additionally, TEMLA showed superior performance in restaging procedures, with a sensitivity of 95.5% and specificity of 100%.
Research suggests that adding an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux does not improve treatment outcomes for cancer patients with blood clots. In fact, median survival was shorter and VTE resolution rates were lower in patients who received both treatments.
Researchers sequenced a patient's entire DNA and RNA to identify the origins of their metastatic adenocarcinoma of the lung, a mutation in the TP53 gene being found to halt tumor suppressor gene creation and result in tumor generation
The study found that trusts with more pure thoracic surgeons saw a significant increase in lung cancer resection rates. In 2009, the overall resection rate rose by 46% due to increased investment in thoracic surgical expertise.
New treatment options, including stereotactic ablative radiotherapy, have led to significant improvements in the survival of elderly Dutch lung cancer patients. Median survival for NSCLC patients increased by nearly 8 months between 2003 and 2009.
A recent study found that celecoxib reduced the Ki-67 labeling index by 34% in former smokers, indicating a potential chemopreventive effect against lung cancer. The medication was also linked to a reduction in lung nodules, a precursor to cancer.
The Cancer Risk Management model uses dynamic simulations to project realistic Canadian populations, offering insights into screening, prevention, and treatment changes. By reducing smoking rates, the model predicts a decrease in lung cancer incidence and cumulative savings in direct treatment costs.
Research reveals disparities in trial populations reflecting U.S. demographics, with women and older patients under-enrolled. Minority groups also show significant underrepresentation, highlighting concerns about toxicity and treatment efficacy.
A new PET imaging technique using [11C]erlotinib may help doctors identify lung cancers that respond well to tyrosine kinase inhibitors (TKIs), enabling personalized therapy. The test showed significantly higher tracer uptake in tumors with activating EGFR mutations, indicating a potential non-invasive predictive marker.
The EURTAC Phase III study found that erlotinib nearly doubled progression-free survival compared to chemotherapy, with a better tolerability profile for Western patients with NSCLC and EGFR activating mutations. The response rate to erlotinib was 54.5%, significantly higher than the 10.5% response rate to chemotherapy.
Research reveals that lung adenocarcinomas in never-smokers exhibit greater genome instability and altered genetic patterns compared to those in smokers. The findings suggest distinct molecular mechanisms driving the development of lung cancer in never-smokers, potentially requiring unique treatments.
Research found that high EGFR expression is a predictor of improved survival in advanced non-small cell lung cancer patients treated with cetuximab and chemotherapy. Patients with high tumor EGFR expression averaged 12 months of overall survival, compared to 9.6 months for those without high expression.
A new study reveals that ALK rearrangement affects nearly 10% of lung cancer patients, while MET amplification occurs in another 4.1%. This could lead to targeted therapy options like crizotinib for these patients.
The LuCED test uses 3D imaging to accurately detect cancer cells in sputum samples from high-risk individuals. This approach can significantly lower the number of false positive cases, making mass screening programs more feasible and cost-effective.
The International Association for the Study of Lung Cancer (IASLC) welcomed the publication of positive results from the National Lung Screening Trial, which showed a 20% reduction in lung cancer deaths and a 7% decrease in all-cause mortality among heavy smokers screened with low-dose spiral computed tomography. The trial followed ove...
A new study published in New England Journal of Medicine found that CT scans can detect lung cancer at an early stage, reducing death rates by 20%. The trial involved over 53,000 current or former heavy smokers and showed improved survival rates for those who received the CT scan.
The study found a significant reduction in lung cancer deaths among heavy smokers screened with low-dose helical CT, with a 20% decrease compared to those screened with chest X-ray. The screening test identified adenocarcinomas and squamous cell carcinomas at early stages of disease, providing valuable insights for future patients.
The National Lung Screening Trial (NLST) found that low-dose helical computed tomography (CT) screening reduced lung cancer deaths among participants who were screened with CT versus those screened with chest X-ray. The study enrolled 53,000 current and former heavy smokers aged 55 to 74.
A large clinical trial found that low-dose spiral CT scanning reduced lung cancer deaths by 20% compared to chest X-ray screening. The study involved over 53,000 participants and provided conclusive evidence of the mortality benefit from CT screening.
A study published in the New England Journal of Medicine confirms that helical low-dose CT scans for lung cancer reduce deaths in heavy smokers by 20 percent. The research also highlights the need for further analysis on cost-effectiveness, downstream consequences, and screening strategies.
The University of Texas M.D. Anderson Cancer Center has introduced a comprehensive lung cancer screening program to detect the disease early. With computed tomography (CT) scans, the program reduces lung cancer-specific mortality by 20%, improving health outcomes for high-risk individuals.
The American Cancer Society's latest report finds a steady decline in overall cancer death rates since the early 1990s, with about 898,000 deaths avoided between 1990 and 2007. However, progress has not benefited all segments of the population equally, with cancer death rates among less-educated individuals being more than twice those ...
A gene linked to emphysema is also found to contribute to lung cancer development, with men showing a higher incidence of the disease. The study suggests that PLAGL2 expression could be used as a marker for cells at risk of malignant transformation.
A clinical trial revealed crizotinib's effectiveness in shrinking tumors and improving responses in over 60% of ALK-positive advanced non-small cell lung cancer patients. The treatment has shown dramatic benefits with minimal side effects, opening new avenues for targeted therapy.
Scientists have identified a drug combination that shows a survival advantage in advanced lung cancer patients who no longer respond to existing therapies. The combination of bexarotene and erlotinib broadens the reach to include patients resistant due to ras mutations, offering new hope for those with limited treatment options.
Researchers found Asian non-small cell lung cancer patients survived longer than Caucasians regardless of the number of chemotherapy drugs given, with improved survival rates after targeted therapies were introduced in the early 2000s.
Five advocacy organizations from India, Australia and the US have been granted travel awards by IASLC to attend the 14th World Conference on Lung Cancer in Amsterdam. The winners will enjoy free registration, accommodation and travel expenses, as well as free IASLC affiliate membership.
End-of-life care for cancer patients varies significantly between the US and Canada, with higher rates of hospital admissions and emergency room visits in Ontario compared to the US. In contrast, US patients receive more chemotherapy, particularly in the last month of life.
Scientists have identified key molecular patterns in the blood of lung cancer patients, which can help detect the disease at an early stage. The study found these patterns are present even in tumors still in their earliest stages, offering new hope for improving lung cancer diagnosis and treatment.